Citius Pharmaceuticals’ (CTXR) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a report issued on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $6.00 price target on the stock.

A number of other equities analysts have also commented on CTXR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen raised Citius Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, December 27th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.00.

Citius Pharmaceuticals Trading Up 10.9%

NASDAQ CTXR opened at $0.96 on Wednesday. The company has a fifty day simple moving average of $0.82 and a 200 day simple moving average of $1.09. The company has a market cap of $21.53 million, a P/E ratio of -0.39 and a beta of 1.51. Citius Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $2.48.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its earnings results on Friday, February 13th. The company reported ($0.38) EPS for the quarter. Equities research analysts forecast that Citius Pharmaceuticals will post -4.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several hedge funds have recently made changes to their positions in CTXR. XTX Topco Ltd acquired a new stake in Citius Pharmaceuticals during the second quarter worth about $32,000. NewEdge Advisors LLC acquired a new position in Citius Pharmaceuticals in the 2nd quarter valued at approximately $40,000. Asset Advisory Group Inc. bought a new stake in shares of Citius Pharmaceuticals in the 4th quarter worth approximately $46,000. Finally, Heights Capital Management Inc. bought a new stake in shares of Citius Pharmaceuticals in the 4th quarter worth approximately $622,000. Institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.